Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Safety and efficacy of antiviral therapy alone or in combination in COVID-19 - a randomized controlled trial (SEV COVID Trial)

SEV COVID trial group, Budha O Singh, Bikram Moirangthem, View ORCID ProfilePrasan Kumar Panda, Yogesh Arvind Bahurupi, Sarama Saha, Girraj Saini, Minakshi Dhar, Mukesh Bairwa, Venkatesh Srinivasa Pai, Ankit Agarwal, Girish Sindhwani, Shailendra Handu, Ravikant
doi: https://doi.org/10.1101/2021.06.06.21258091
1Department of Internal Medicine, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India
Budha O Singh
1Department of Internal Medicine, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bikram Moirangthem
1Department of Internal Medicine, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Prasan Kumar Panda
1Department of Internal Medicine, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Prasan Kumar Panda
  • For correspondence: motherprasanna{at}rediffmail.com
Yogesh Arvind Bahurupi
2Community and Family Medicine, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarama Saha
3Biochemistry, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Girraj Saini
4Nursing, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Minakshi Dhar
1Department of Internal Medicine, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mukesh Bairwa
1Department of Internal Medicine, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Venkatesh Srinivasa Pai
1Department of Internal Medicine, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ankit Agarwal
5Anesthesia and Critical Care Medicne, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Girish Sindhwani
6Pulmonary Medicine, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shailendra Handu
7Pharmacology, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ravikant
8Director, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Definitive antiviral treatment is not available for COVID-19 infection except remdesivir that even with many doubts. Various combination antivirals have been tried.

Methods A single-center, open-label, parallel-arm, stratified randomized controlled trial evaluated the therapeutic potential of hydroxychloroquine and lopinavir-ritonavir in combination with ribavirin in COVID-19. Enrolled patients in severe category were randomized into three groups: A: standard treatment, B: hydroxychloroquine+ribavirin+standard treatment, or C: lopinavir+ritonavir+ribavirin+standard treatment; while non-severe category into two groups: A: standard treatment or B: hydroxychloroquine+ribavirin. Combination antivirals was given for 10 days and followed for 28 days. The primary endpoints were safety, symptomatic and laboratory recovery of organ dysfunctions, and time to SARS-CoV-2 RT-PCR negative report.

Results Total 111 patients randomized: 24, 23, and 24 in severe category A, B, and C respectively, and 20 in each non-severe group. Two patients receiving ribavirin experienced drug induced liver injury and another developed QT prolongation after hydroxychloroquine. In the severe category, 47.6%, 55%, and 30.09% in A, B, and C groups respectively showed symptomatic recovery compared to 93.3% and 86.7% in A and B groups respectively in the non-severe category at 72hrs (P>0.05).

Conclusions The results failed to show statistical superiority of the antiviral combination therapies to that of the standard therapy in both the severe and non-severe categories in symptomatic adult patients of COVID-19. However, results do indicate the benefit of non-standard interventional combination therapy in severe disease. Furthermore, the dose of ribavirin needs to be reconsidered in the Indian population.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

CTRI/2020/06/025575

Funding Statement

Non-funded

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This trial was approved by the Institutional Ethics Committee of AIIMS, Rishikesh on 30/05/2020 with reference no. 218/IEC/IM/NF/2020. Written informed consent was obtained from all participants.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

It will be provided with permission from the Corresponding author.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted June 08, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Safety and efficacy of antiviral therapy alone or in combination in COVID-19 - a randomized controlled trial (SEV COVID Trial)
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Safety and efficacy of antiviral therapy alone or in combination in COVID-19 - a randomized controlled trial (SEV COVID Trial)
SEV COVID trial group, Budha O Singh, Bikram Moirangthem, Prasan Kumar Panda, Yogesh Arvind Bahurupi, Sarama Saha, Girraj Saini, Minakshi Dhar, Mukesh Bairwa, Venkatesh Srinivasa Pai, Ankit Agarwal, Girish Sindhwani, Shailendra Handu, Ravikant
medRxiv 2021.06.06.21258091; doi: https://doi.org/10.1101/2021.06.06.21258091
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Safety and efficacy of antiviral therapy alone or in combination in COVID-19 - a randomized controlled trial (SEV COVID Trial)
SEV COVID trial group, Budha O Singh, Bikram Moirangthem, Prasan Kumar Panda, Yogesh Arvind Bahurupi, Sarama Saha, Girraj Saini, Minakshi Dhar, Mukesh Bairwa, Venkatesh Srinivasa Pai, Ankit Agarwal, Girish Sindhwani, Shailendra Handu, Ravikant
medRxiv 2021.06.06.21258091; doi: https://doi.org/10.1101/2021.06.06.21258091

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (427)
  • Allergy and Immunology (753)
  • Anesthesia (220)
  • Cardiovascular Medicine (3281)
  • Dentistry and Oral Medicine (362)
  • Dermatology (274)
  • Emergency Medicine (478)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1164)
  • Epidemiology (13341)
  • Forensic Medicine (19)
  • Gastroenterology (897)
  • Genetic and Genomic Medicine (5132)
  • Geriatric Medicine (479)
  • Health Economics (781)
  • Health Informatics (3254)
  • Health Policy (1138)
  • Health Systems and Quality Improvement (1189)
  • Hematology (427)
  • HIV/AIDS (1014)
  • Infectious Diseases (except HIV/AIDS) (14613)
  • Intensive Care and Critical Care Medicine (910)
  • Medical Education (475)
  • Medical Ethics (126)
  • Nephrology (522)
  • Neurology (4905)
  • Nursing (261)
  • Nutrition (725)
  • Obstetrics and Gynecology (880)
  • Occupational and Environmental Health (795)
  • Oncology (2516)
  • Ophthalmology (722)
  • Orthopedics (280)
  • Otolaryngology (346)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (540)
  • Pediatrics (1298)
  • Pharmacology and Therapeutics (548)
  • Primary Care Research (554)
  • Psychiatry and Clinical Psychology (4194)
  • Public and Global Health (7483)
  • Radiology and Imaging (1702)
  • Rehabilitation Medicine and Physical Therapy (1010)
  • Respiratory Medicine (979)
  • Rheumatology (478)
  • Sexual and Reproductive Health (495)
  • Sports Medicine (424)
  • Surgery (546)
  • Toxicology (71)
  • Transplantation (235)
  • Urology (203)